



30 August 2021

## Tender results

Pharmac has resolved to award tenders for Principal Supply Status for some products included in the 2020/21 Invitation to Tender, dated 2 November 2020 and has resolved to award tenders for Sole Subsidised Supply Status and Hospital Supply Status for some products included in the 2019/20 Invitation to Tender dated 1 November 2019.

Some of the pharmaceuticals that will be delisted when the period of Principal Supply Status, Sole Subsidised Supply or Hospital Supply Status commences may be subject to existing listing contracts with Pharmac. Suppliers of pharmaceuticals that are subject to such contracts should continue to supply their pharmaceuticals under those contracts. Pharmac will continue to subsidise those pharmaceuticals accordingly until such time as those pharmaceuticals are delisted.

## Notification of Product Changes (NOPC) forms

Please note that for any changes (price change, pack size change, new listing etc) to be effective in the Pharmaceutical Schedule (including Section H), suppliers are required to submit a Notification of Product Changes (NOPC) form to Pharmac, the Pharmacy Guild and the NZULM by:

- **For new listings**, by 4pm on the 12<sup>th</sup> of September 2021 or the 5<sup>th</sup> of the month prior to listing, whichever is earlier
- **For price changes**, by 4pm on the 12<sup>th</sup> of the month prior to the date of subsidy change

Pharmac cannot list a product (and pharmacies cannot claim) without this information. More information about this process, and a copy of the NOPC form can be found on our website – <https://pharmac.govt.nz/medicine-funding-and-supply/make-an-application/pharmconnect-make-a-medicine-funding-application/process-for-notification-of-product-changes/>

Suppliers are required to ensure that a Pharmacode has been obtained from the Pharmacy Guild of New Zealand (<http://www.pgnz.org.nz/about-us-1/pharmacode>) and that a CTPP code has been obtained from the New Zealand Universal List of Medicines (<http://www.nzulm.org.nz/sponsors>). Pharmacodes and CTPP codes must be provided to Pharmac by the 5<sup>th</sup> of the month prior to the date of listing, or 10 business days following the market notification date (whichever is earliest). Pharmac cannot list a product (and pharmacies cannot claim) without the correct Pharmacode.

**Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule**

1. *Tenders awarded to pharmaceuticals where no brand is listed.*

The decisions were as follows:

| Chemical name             | Presentation;<br>Pack size and type | New<br>pack price | Sole supply brand<br>(Supplier)   | Listing date    | Sole Subsidised Supply<br>date |
|---------------------------|-------------------------------------|-------------------|-----------------------------------|-----------------|--------------------------------|
| Rosuvastatin <sup>1</sup> | Tab 5 mg; 30 tablet blister pack    | \$1.70            | Rosuvastatin Viatris<br>(Viatris) | 1 December 2021 | 1 May 2022                     |
| Rosuvastatin <sup>1</sup> | Tab 10 mg; 30 tablet blister pack   | \$2.42            | Rosuvastatin Viatris<br>(Viatris) | 1 December 2021 | 1 May 2022                     |
| Rosuvastatin <sup>1</sup> | Tab 20 mg; 30 tablet blister pack   | \$3.92            | Rosuvastatin Viatris<br>(Viatris) | 1 December 2021 | 1 May 2022                     |
| Rosuvastatin <sup>1</sup> | Tab 40 mg; 30 tablet blister pack   | \$5.28            | Rosuvastatin Viatris<br>(Viatris) | 1 December 2021 | 1 May 2022                     |

<sup>1</sup>Subject to Special Authority criteria as notified on [17 August 2021](#).

**Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule**

2. *Tenders awarded to pharmaceuticals where no brand is listed.*

The decisions were as follows:

| Chemical name             | Presentation;<br>Pack size and type | New<br>pack price | Hospital Supply brand<br>(Supplier) | DV<br>Limit | Listing date    | Hospital Supply Status date |
|---------------------------|-------------------------------------|-------------------|-------------------------------------|-------------|-----------------|-----------------------------|
| Rosuvastatin <sup>2</sup> | Tab 5 mg; 30 tablet blister pack    | \$1.70            | Rosuvastatin Viatris<br>(Viatris)   | 1%          | 1 December 2021 | 1 May 2022                  |
| Rosuvastatin <sup>2</sup> | Tab 10 mg; 30 tablet blister pack   | \$2.42            | Rosuvastatin Viatris<br>(Viatris)   | 1%          | 1 December 2021 | 1 May 2022                  |
| Rosuvastatin <sup>2</sup> | Tab 20 mg; 30 tablet blister pack   | \$3.92            | Rosuvastatin Viatris<br>(Viatris)   | 1%          | 1 December 2021 | 1 May 2022                  |
| Rosuvastatin <sup>2</sup> | Tab 40 mg; 30 tablet blister pack   | \$5.28            | Rosuvastatin Viatris<br>(Viatris)   | 1%          | 1 December 2021 | 1 May 2022                  |

<sup>2</sup>Hospital Restriction criteria will apply as notified on [17 August 2021](#).

**Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule**

*3. Tenders awarded to currently listed pharmaceuticals where at least one other brand is listed*

The decisions were as follows:

| Chemical name           | Presentation;<br>Pack size and type              | Current<br>pack price | New<br>pack price | Principal Supply brand<br>(Supplier) | Date of subsidy<br>change | Principal Supply<br>Status date | Brand<br>(Supplier)<br>affected by delisting |
|-------------------------|--|-----------------------|-------------------|--------------------------------------|---------------------------|---------------------------------|--|
| Neostigmine metisulfate | Inj 2.5 mg per ml, 1 ml ampoule; 10 ampoule pack | \$29.40               | \$33.81           | Max Health<br>(Max Health)           | 1 October 2021            | 1 March 2022                    | AstraZeneca<br>(Juno)<br>Juno<br>(Juno)      |
| Sunitinib               | Cap 12.5 mg; 28 capsule blister pack             | \$2,315.38            | \$208.38          | Sunitinib Pfizer<br>(Pfizer)         | 1 February 2022           | 1 July 2022                     | Sutent<br>(Pfizer)                           |
| Sunitinib               | Cap 25 mg; 28 capsule blister pack               | \$4,630.77            | \$416.77          | Sunitinib Pfizer<br>(Pfizer)         | 1 February 2022           | 1 July 2022                     | Sutent<br>(Pfizer)                           |
| Sunitinib               | Cap 50 mg; 28 capsule blister pack               | \$9,261.54            | \$694.62          | Sunitinib Pfizer<br>(Pfizer)         | 1 February 2022           | 1 July 2022                     | Sutent<br>(Pfizer)                           |

**Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule**

*4. Tenders awarded to currently listed pharmaceuticals where at least one other brand is listed*

The decisions were as follows:

| Chemical name           | Presentation;<br>Pack size and type              | Current<br>pack price | New<br>pack price | Principal Supply brand<br>(Supplier) | DV<br>Limit | Listing date   | Principal<br>Supply Status<br>date | Brand<br>(Supplier)<br>affected by delisting |
|-------------------------|--|-----------------------|-------------------|--------------------------------------|-------------|----------------|------------------------------------|--|
| Neostigmine metisulfate | Inj 2.5 mg per ml, 1 ml ampoule; 10 ampoule pack | \$98.00<br>(per 50)   | \$33.81           | Max Health<br>(Max Health)           | 5%          | 1 October 2021 | 1 March 2022                       | AstraZeneca<br>(Juno)                        |
| Sugammadex              | Inj 100 mg per ml, 2 ml vial;<br>10 vial pack    | \$1,200.00            | \$384.00          | Sugammadex BNM<br>(Boucher)          | 5%          | 1 March 2022   | 1 August 2022                      | Bridion<br>(MSD)                             |
| Sugammadex              | Inj 100 mg per ml, 5 ml vial;<br>10 vial pack    | \$3,000.00            | \$960.00          | Sugammadex BNM<br>(Boucher)          | 5%          | 1 March 2022   | 1 August 2022                      | Bridion<br>(MSD)                             |

| Chemical name | Presentation;<br>Pack size and type     | Current<br>pack<br>price | New<br>pack<br>price | Principal Supply brand<br>(Supplier) | DV<br>Limit | Listing date    | Principal<br>Supply Status<br>date | Brand<br>(Supplier)<br>affected by delisting |
|---------------|---|--------------------------|----------------------|--------------------------------------|-------------|-----------------|------------------------------------|--|
| Sunitinib     | Cap 12.5 mg; 28 capsule<br>blister pack | \$2,315.38               | \$208.38             | Sunitinib Pfizer<br>(Pfizer)         | 5%          | 1 February 2022 | 1 July 2022                        | Sutent<br>(Pfizer)                           |
| Sunitinib     | Cap 25 mg; 28 capsule blister<br>pack   | \$4,630.77               | \$416.77             | Sunitinib Pfizer<br>(Pfizer)         | 5%          | 1 February 2022 | 1 July 2022                        | Sutent<br>(Pfizer)                           |
| Sunitinib     | Cap 50 mg; 28 capsule blister<br>pack   | \$9,261.54               | \$694.62             | Sunitinib Pfizer<br>(Pfizer)         | 5%          | 1 February 2022 | 1 July 2022                        | Sutent<br>(Pfizer)                           |

## Tender declines - Products where no tender is to be awarded for Principal Supply Status

Pharmac has resolved not to award tenders for Principal Supply Status for the following products listed in:

- the 2020/21 Invitation to Tender, dated 2 November 2020

### *2020/21 Invitation to Tender*

| Chemical name              | Line item   |
|----------------------------|-------------|
| Sunitinib (current access) | Cap 37.5 mg |
| Sunitinib (widened access) | Cap 12.5 mg |
| Sunitinib (widened access) | Cap 25 mg   |
| Sunitinib (widened access) | Cap 37.5 mg |
| Sunitinib (widened access) | Cap 50 mg   |

For products included in the 2018/19, 2019/20 and 2020/21 Invitation to Tender where no announcement has yet been made, either a decision is still pending or is provisional, subject to the product gaining market approval and being available to supply, and subject to Pharmac Board (or its delegate) approval. We will keep you informed of any updates regarding such tender products as decisions are made. If you have any queries regarding this notification, please contact Pharmac on 0800 66 00 50.